Localized anti-inflammatory CD39/CD73 therapy to prevent multi-organ failure in hemorrhagic shock by targeted adenosine production.

Engineered patient-specific bone marrow model predicts cancer metastasis and therapy response from serum in a non-invasive diagnostic.

Bioengineered 3D human bone marrow niche from iPSCs for drug discovery, toxicity testing, and personalized hematologic research.

Monoclonal antibody against Annexin A1 blocks Fusobacterium nucleatum invasion, offering targeted prevention and treatment of Fn-related cancers.

An optical catheter using infrared and OCT spectrometry enables noninvasive, real-time differentiation of uterine cancer and fibroids.

3D squamous epithelial organoids enable patient-specific disease modeling and rapid, predictive drug testing for ESCC/EAC.

Patient-specific pancreatic cancer organoids with patient immune cells enable high-throughput drug screening and personalized therapy insights.

Selective peptide nucleic acid polymers block cancer gene expression, targeting mutations like BRAFV600E with improved delivery and specificity.

Short cell-penetrating truncated inhibitors target ATF5/CEBPB/CEBPD, suppressing cancer survival across tumor types.

Multi-tissue, vascularized organ-on-a-chip platform enables patient-specific, long-term modeling of systemic disease and metastasis.

Integrated ssg- and sscf-MeDIP-Seq detect methylation and hemi-methylation for higher-precision tumor diagnosis via cfDNA.

Retinoid pathway inverse agonists reprogram ACC cells to non-tumorigenic states, enabling targeted differentiation and death.

Bispecific SLAMF6 antibodies compartmentalize T cells to enhance activation, enabling targeted cancer immunotherapy with fewer off-target effects.

A tagmentation-based, antibody-free MeDIP-seq method streamlines DNA methylation analysis with less input DNA and faster library prep.

Non-invasive methylation profiling of tumor cfDNA enables early cancer detection, tumor origin, and targeted treatment insights.